Thinly traded micro cap Albireo Pharma (NASDAQ:ALBO) is down 12% after hours on light volume in reaction to topline results from a Phase 2 clinical trial evaluating constipation med elobixibat for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
The 47-subject study met the primary endpoint demonstrating a statistically significant change from baseline in LDL-cholesterol (“bad” cholesterol) at week 16 compared to placebo but failed to achieve any of the secondary NASH endpoints thereby failing to show proof-of-concept.
The company will cease development in NASH as a result.
The oral ileal bile acid transporter inhibitor is marketed in Japan under the brand name GOOFICE.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.